Navigation Links
New Pill Appears Effective, Safe for Ulcerative Colitis: Study
Date:8/15/2012

By Serena Gordon
HealthDay Reporter

WEDNESDAY, Aug. 15 (HealthDay News) -- An experimental drug called tofacitinib reduces the symptoms of ulcerative colitis, at least in the short term. The drug appears relatively safe, with few serious side effects, a new study found.

More than three-quarters of those taking the highest dose of the drug -- which is given as a pill -- had a response to the medication, and 41 percent of these patients achieved a remission, according to the study.

"Tofacitinib . . . affects a group of proteins expressed in the white blood cells. It has a suppressive effect on the immune system," explained the study's lead author, Dr. William Sandborn, chief of gastroenterology and head of the Inflammatory Bowel Disease Center at the University of California, San Diego.

"Ulcerative colitis leads to rectal bleeding, diarrhea and other symptoms that affect a patient's quality of life. The immune system is attacking the colon in ulcerative colitis, and the theory behind this drug is that you would block the function of the immune system cells that are causing the problems and lead to an improvement in the disease," Sandborn said.

Results of the study are published in the Aug. 16 issue of the New England Journal of Medicine. The drug's manufacturer, Pfizer, provided funding for the study, and Pfizer researchers were involved in the design and implementation of the study, according to Sandborn.

Ulcerative colitis is a chronic inflammatory disease of the colon that affects about 700,000 Americans, according to the Crohn's and Colitis Foundation of America. The treatment options for the disease are somewhat limited, and the treatments that are available, such as corticosteroids, have many unwanted side effects. Drugs may be used to bring a flare-up of ulcerative colitis into remission or to maintain a remission. Corticosteroids are generally used to induce a remission, but not maintain it, because of their numerous side effects.

Another drug, called infliximab (Remicade), is used to induce and maintain remission in ulcerative colitis. The current study only looked at short-term use of tofacitinib. It's unclear yet whether the drug could be used for maintenance therapy.

The current study included 194 adults with moderately to severely active ulcerative colitis who were randomly assigned to receive one of four doses of the drug or an inactive placebo twice daily for eight weeks. The drug dosages used were 0.5 milligrams (mg), 3 mg, 10 mg or 15 mg.

The medication was considered to have produced a clinical response if someone had a decrease in their symptom score of 3 or more on a scale of zero to 12, with 12 indicating the most severe disease, or if they had a decrease in their symptoms by 30 percent or more from their baseline score and had an accompanying decrease in rectal bleeding.

Clinical responses occurred in 32 percent, 48 percent, 61 percent and 78 percent of those receiving the medication, respectively, correlating directly with the dose they were taking. The lowest response rate was seen for the 0.5-mg dose, while the highest response was seen in those taking the 15-mg dose. In those taking a placebo, 42 percent had a clinical response.

Remission was achieved by eight weeks in 13 percent, 33 percent, 48 percent and 41 percent of those taking the lowest to highest doses. Ten percent of those on placebo achieved remission, the report noted.

The researchers noted a rise in both good and bad cholesterol that increased as the dose of medication went higher. Three patients had low white blood cell counts, which increases the possibility of infection, according to the study.

"It does seem clear that this drug has a clinical benefit. The 10- to 15-mg twice-a-day dose looks promising for further studies that will look at inducing remission and taking the drug chronically. Can you maintain these benefits over time in a reasonably safe manner?" Sandborn said.

Another expert commented on the study results.

"This drug is taking a new approach and, clearly, at higher doses, it showed a statistically significant effect in terms of response and remission," said Dr. Michael Poles, a gastroenterologist and associate professor of medicine at New York University School of Medicine in New York City.

But, Poles said he felt the study had a higher rate of adverse events than he likes to see, and he'd like to see long-term results. In addition, he noted, because there are other medications with a longer track record already available, he'd be hesitant to prescribe this new drug until he'd exhausted other options first.

"The drug is worthy of further study, but it may not be the panacea we hoped for," Poles said.

More information

Learn more about ulcerative colitis from the U.S. National Library of Medicine.

SOURCES: William Sandborn, M.D., chief, gastroenterology, and head, Inflammatory Bowel Disease Center, University of California, San Diego; Michael Poles, M.D., gastroenterologist and associate professor of medicine, New York University School of Medicine, New York City; Aug. 16, 2012, New England Journal of Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Exercise Appears to Ease Nerve-Damage Pain in Rat Study
2. Off-Label Drug Use Appears Common
3. Herbal remedy used to treat hepatitis C proves ineffective, Penn study finds
4. NYU School of Medicine announces new clinical trial for ulcerative colitis
5. PSA Tests Overall Benefit Still Unclear: Study
6. Drinking in Pregnancy Shows Up in Childs Growth: Study
7. Routine Screening Wont Cut Rates of Domestic Violence, Study Suggests
8. Poor Economy Tied to Rise in Suicides, British Study Finds
9. By studying animal health, researchers find improved ways for developing, testing cancer therapies
10. Study: Vaccine targets malignant brain cancer antigens, significantly lengthens survival
11. Your Blood Type May Boost Your Heart Risk, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Pill Appears Effective, Safe for Ulcerative Colitis: Study
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology: